Cell and gene therapies from academia: EMA to help 5 projects going after unmet clinical needs
The European Medicines Agency said Thursday that it’s launching a new pilot program to help academic and other nonprofit researchers developing advanced therapy medicinal products, which includes cell and gene therapies.
Academics have proven to be enormously useful in feeding new products, like chimeric antigen receptor (CAR)-T cell therapies, some of which were first developed by Memorial Sloan Kettering Cancer Center and the University of Pennsylvania, and ushered to the market by biopharma companies. Jean Bennett, formerly with the University of Pennsylvania, also saw her research lead to the approval of gene therapy Luxturna, which Roche now owns.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.